BCL2 and non-small cell lung carcinoma: Several studies showed that inhibiting anti-apoptotic proteins of the B-cell lymphoma 2 (Bcl-2) [9], [10] or inhibitor of apoptosis (IAP) families [11], [12] sensitizes NSCLC cells to chemotherapy.